[The treatment of influenza and acute respiratory viral infections]

Related Experiment Video

Updated: May 2, 2026

A Luciferase-fluorescent Reporter Influenza Virus for Live Imaging and Quantification of Viral Infection
05:21

A Luciferase-fluorescent Reporter Influenza Virus for Live Imaging and Quantification of Viral Infection

Published on: August 14, 2019

28.9K

S A Kramarev, A P Moshchich

    Likars'Ka Sprava
    |March 11, 2014
    PubMed

    Insights

    Umifenovir is a fusion inhibitor effective against various respiratory viruses, including influenza. Clinical studies demonstrate its prophylactic and therapeutic benefits for acute respiratory viral infections (ARVI).

    Area of Science:

    • Virology
    • Pharmacology
    • Immunology

    Background:

    • Acute respiratory viral infections (ARVI) and influenza are leading causes of global morbidity.
    • Antiviral drugs are crucial for treating and preventing these infections.
    • Umifenovir is a widely used antiviral drug acting as a fusion inhibitor.

    Purpose of the Study:

    • To review the antiviral activity and clinical efficacy of umifenovir.
    • To highlight the role of nanotechnological products in ARVI management.

    Main Methods:

    • In vitro studies assessing umifenovir's activity against various respiratory viruses.
    • Clinical trials evaluating the prophylactic and therapeutic efficacy of umifenovir in large patient cohorts.

    Main Results:

    • Umifenovir demonstrated in vitro activity against rhinovirus, adenovirus, influenza, parainfluenza, RSV, and coronaviruses.
    • Clinical studies involving over 12,000 individuals showed umifenovir's effectiveness in prophylaxis and treatment.
    • Natural nanotechnological products like anaferon, aflubin, and oscillococcinum possess antiviral and immunomodulatory properties.

    Conclusions:

    • Umifenovir is a clinically effective antiviral agent against a broad spectrum of respiratory viruses.
    • Nanotechnological products offer complementary benefits in managing influenza and ARVI.

    More Related Videos

    Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses09:07

    Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses

    Published on: January 20, 2017

    9.8K
    Rapid Molecular Detection and Differentiation of Influenza Viruses A and B05:38

    Rapid Molecular Detection and Differentiation of Influenza Viruses A and B

    Published on: January 30, 2017

    15.2K

    Related Concept Videos

    Influenza01:27

    Influenza

    Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
    87
    Pneumonia IV: Management01:28

    Pneumonia IV: Management

    The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
    Bacterial Pneumonia Treatment
    For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
    1.2K
    Acute Respiratory Failure-V01:29

    Acute Respiratory Failure-V

    The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
    Ensure that patients are monitored continuously for their response to therapy, including changes in...
    768
    Acute Pharyngitis01:30

    Acute Pharyngitis

    Introduction
    Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
    Classification
    Acute pharyngitis can be categorized based on its underlying cause:
    6.6K
    Drugs Used in Upper Respiratory Disorders: Overview01:16

    Drugs Used in Upper Respiratory Disorders: Overview

    Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
    Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
    1.0K
    Inhibitors of Viral Protein Synthesis01:30

    Inhibitors of Viral Protein Synthesis

    Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
    58